Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human PEDF ELISA Kit (AC2565)
Cat.#: ASET-1154
Specifications
Description Human PEDF ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human PEDF concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.017 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 0.75-12 ng/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1079 Human Synapsin I ELISA Kit (AC2490) Quantitative inquiry ASET-1568 Human GPCR GPR35 ELISA Kit (AC2979) Quantitative inquiry ASET-2467 Human Attractin ELISA Kit (AC3878) Quantitative inquiry ASET-1762 Human GDF7 ELISA Kit (AC3173) Quantitative inquiry ASET-2178 Mouse Aldh1a7 ELISA Kit (AC3589) Quantitative inquiry ASET-1147 Human AANAT ELISA Kit (AC2558) Quantitative inquiry ASET-2496 Human KAL1 ELISA Kit (AC3907) Quantitative inquiry ASET-1831 Human SFRP1 ELISA Kit (AC3242) Quantitative inquiry ASET-1262 Human PACAP ELISA Kit (AC2673) Quantitative inquiry ASET-2349 Human BDNF ELISA Kit (AC3760) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket